Could Microbiome-Based Therapeutics Fill the Unmet Need in Recurrent Clostridioides Difficile (C. Diff) Treatment? Spherix Investigates
/PRNewswire/ -- Spherix recently surveyed 76 gastroenterologists and 26 infectious disease (ID) physicians (including 8 qualitative interviews between both...
Eric John Prnewswire Spherix Destiny Pharmaceuticals Market Dynamix Clostridiodes Difficile Seres Therapeutics
Source: prnewswire.com